Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria

•Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.•Pegcetacoplan’s comprehensive control of hemolysis and favorable safety profile in these patients may help expand the treatment population. [Display omitted] Paroxysmal...

Celý popis

Podrobná bibliografia

Vydané v:	Blood advances Ročník 7; číslo 11; s. 2468 - 2478
Hlavní autori:	Wong, Raymond Siu Ming, Navarro-Cabrera, Juan Ramon, Comia, Narcisa Sonia, Goh, Yeow Tee, Idrobo, Henry, Kongkabpan, Daolada, Gómez-Almaguer, David, Al-Adhami, Mohammed, Ajayi, Temitayo, Alvarenga, Paulo, Savage, Jessica, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Dumagay, Teresita
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 13.06.2023 The American Society of Hematology
Predmet:	Adult Antibodies, Monoclonal, Humanized - adverse effects Clinical Trials and Observations Complement Inactivating Agents - adverse effects Hemoglobins Hemoglobinuria, Paroxysmal - drug therapy Hemolysis Humans L-Lactate Dehydrogenase
ISSN:	2473-9529, 2473-9537, 2473-9537
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!